Trial Profile
A phase 2 trial of Nivolumab in recurrent or metastatic platinum-refractory non-squamous cell carcinoma of the head and neck
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Head and neck cancer; Parotid cancer; Salivary gland cancer
- Focus Therapeutic Use
- Acronyms HN non-SCC_P2_Nivo
- 06 Jun 2023 Primary endpoint (Objective response rate (ORR)) has not been met, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results (between March 2018 and January 2022) assessing the efficacy and safety of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 24 Oct 2022 Status changed from recruiting to active, no longer recruiting.